Leave message
Can’t find what you’re looking for?
Fill out this form to inquire about our custom protein services!
Inquire about our Custom Services >>
Limited Edition Golden Llama is here! Check out how you can get one. Limited Edition Golden Llama is here! Check out how you can get one.
Offering SPR-BLI Services - Proteins provided for free!Get your ComboX free sample to test now!
Time Limited Offer: Welcome Gift for New Customers ! Shipping Price Reduction for EU Regions
This protein carries a polyhistidine tag at the C-terminus, followed by an Avi tag (Avitag™).
The protein has a calculated MW of 16.9 kDa. The protein migrates as 32-44 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
>95% as determined by SDS-PAGE.
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
Biotinylated Human CD47, His,Avitag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%.
Immobilized Monoclonal Anti-Human CD47 Antibody, Human IgG4 at 2 μg/mL (100 μL/well) can bind Biotinylated Human CD47, His,Avitag (Cat. No. CD7-H82E9) with a linear range of 0.1-3 ng/mL (QC tested).
Immobilized Human SIRP alpha, Fc Tag (Cat. No. SIA-H5251) at 2 μg/mL (100 μL/well) can bind Biotinylated Human CD47, His,Avitag (Cat. No. CD7-H82E9) with a linear range of 2-25 ng/mL (Routinely tested).
FACS assay shows that Biotinylated Human CD47, His,Avitag (Cat. No. CD7-H82E9) can bind to ACHN cell expressing human SIRP-a. The concentration of CD47 used is 10 μg/mL (Routinely tested).
FACS analysis shows that the binding of Human CD47 to ACHN expressing SIRP-a was inhibited by increasing concentration of neutralizing SIRP-a antibody. The concentration of Human CD47 used is 20 μg/mL. IC50=9.334 μg/mL
Price(EUR) : €350.00
Price(EUR) : €1540.00
Price(EUR) : €30.00
Price(EUR) : €140.00
Price(EUR) : €50.00
Price(EUR) : €120.00
Price(EUR) : €140.00
Price(EUR) : €230.00
Explore our catalog of therapeutic antibody solutions to find the right products for you! We are dedicated to delivering solutions designed to help you drive innovation and push the boundaries of what therapeutic antibodies can be.
We offer a wide range of cell and gene therapy solutions starting from discovery to the clinic. Explore our wide range of proteins, antibodies, kits, and other assays to accelerate the development of your cell and gene therapy.
Organoid Toolbox is a collection of organoid solutions including ready-to-use organoids, organoid differentiation kits, and a variety of services to accelerate the progress of your drug development project.
ACROBiosystems developed a series of GMP grade cytokines under the GMP grade quality management system. Those products are all suitable for T/NK cell generation, activation, and proliferation in cell therapy research.
50+ targets designed for CAR detection, including PE/FITC/biotin labeled proteins. The key reagents for CD19 and BCMA were FDA DMF filed which can support your IND, NDA and BLA process.
GMP grade cytokines, reagents for cell activation, gene edition, DNA/RNA removal, etc. Particularly focus on product design, quality control and solution-based support to link each phase of your cell and gene therapy journey.
Full length multi-pass TPs with stabilized structure and high bioactivity for immunization, antibody screening, cell based assay and CAR detection, including hot CD20, Claudin 18.2, CD133, GPRC5D,CCR8, CCR5, etc.
A series of immune checkpoints including classic co-inhibitory and co-stimulatory receptors. The comprehensive catalog contains 100+ targets with various species and tags, and the high-quality proteins are in good batch-to-batch consistency.
To meet the needs of ADCs development, ACROBiosystems can provide: A variety of high-quality target proteins; MMPs/Cathepsin/uPA for cleavable linker; Anti-payload antibodies & anti-idiotypic antibodies for immunogenicity and PK analysis; SPR/BLI analytical and ADA development service.
Comprehensive collection of Fc receptor proteins, including their common variants, which can help expedite your antibody development.
Comprehensive cytokine targets including interleukins, growth factors, chemokines, TNFs, etc. are expressed by HEK293 to ensure their natural structure. Their high purity is verified by SDS-PAGE/HPLC/SEC-MALS and high bioactivity is verified by ELISA/SPR/BLI.
Aneuro provides innovative solutions for neuroscience research. Recombinant proteins, neural factors, pre-formed fibrils, electrophysiological electrodes, as well as Organoid Toolbox all in Aneuro aiming to advance neuroscience research, develop therapeutic interventions, and improve diagnostic methods for neurological diseases.
English Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Fecha | Indications | Clinical Trials |
---|
English Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
Evorpacept | ALX148; ALX-148 | Phase 3 Clinical | Alexo Therapeutics | Urinary Bladder Neoplasms; Neoplasm Metastasis; Lymphoma; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin; Colorectal Neoplasms; Primary mediastinal B cell lymphoma; Richter's Syndrome; Lymphoma, Mantle-Cell; Lymphoma, Follicular; Plasmablastic Lymphoma; Solid tumours; Carcinoma, Transitional Cell; Composite Lymphoma; Neoplasms; Myelodysplastic Syndromes; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Esophageal Neoplasms; Lymphoma, B-Cell, Marginal Zone; Lymphoma, B-Cell; Head and Neck Neoplasms | Details |
Lemzoparlimab | TJC-4; ABBV-IMAB-TJC4; TJ-1133; TJ-011133 | Phase 3 Clinical | I-Mab Biopharma Co Ltd, Abbvie Inc | Solid tumours; Hematologic Neoplasms; Myelodysplastic Syndromes; Multiple Myeloma; Leukemia, Myeloid, Acute; Lymphoma | Details |
Magrolimab | 5-F-9; Hu5F9-G4; ONO-7913 | Phase 2 Clinical | Stanford University | Urinary Bladder Neoplasms; Mycosis Fungoides; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell, Cutaneous; Leukemia, Myeloid, Acute; Sezary Syndrome; Colorectal Neoplasms; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Osteosarcoma; Neuroblastoma; Brain Neoplasms; Multiple Myeloma; Solid tumours; Triple Negative Breast Neoplasms; Myelodysplastic Syndromes; Hodgkin Disease; Lymphoma, Large B-Cell, Diffuse; Carcinoma, Transitional Cell; Leukemia, Lymphoid; Squamous Cell Carcinoma of Head and Neck; Lymphoma, B-Cell, Marginal Zone; Leukemia, Myeloid; Ovarian Neoplasms; Lymphoma, B-Cell | Details |
Timdarpacept | IMM01; IMM 01 | Phase 2 Clinical | ImmuneOnco Biopharmaceuticals (Shanghai) Co Ltd | Solid tumours; Leukemia, Promyelocytic, Acute; Myelodysplastic Syndromes; Hodgkin Disease; Multiple Myeloma; Lymphoma, Extranodal NK-T-Cell; Leukemia, Myeloid, Acute; Lymphoma; Lymphoma, Non-Hodgkin | Details |
AO-176 | AO-176; Ti-104; Ti-108; Ti-176 | Phase 2 Clinical | Arch Oncology Inc | Solid tumours; Multiple Myeloma | Details |
Ontorpacept | TTI-621 | Phase 2 Clinical | The Hospital For Sick Children, University Health Network, Trillium Therapeutics Inc | Multiple Myeloma; Mycosis Fungoides; Melanoma; Carcinoma, Squamous Cell; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell; Sarcoma; Breast Neoplasms; Primary mediastinal B cell lymphoma; Lymphoma, Follicular; Leiomyosarcoma; Neoplasms; Papillomavirus Infections; Skin Neoplasms; Lymphoma, Large B-Cell, Diffuse; Carcinoma, Merkel Cell; Hematologic Neoplasms; Solid tumours; Lymphoma, B-Cell | Details |
IMM-0306 | IMC-002; IMM-0306 | Phase 2 Clinical | ImmuneOnco Biopharmaceuticals (Shanghai) Co Ltd | Lymphoma, B-Cell; Lymphoma, Non-Hodgkin | Details |
Ligufalimab | AK-117 | Phase 2 Clinical | Zhongshan Akeso Biopharma Co Ltd | Solid tumours; Esophageal Neoplasms; Stomach Neoplasms; Squamous Cell Carcinoma of Head and Neck; Neoplasms; Myelodysplastic Syndromes; Triple Negative Breast Neoplasms; Breast Neoplasms; Leukemia, Myeloid, Acute; Lymphoma | Details |
Maplirpacept | TTI-622; PF-07901801 | Phase 2 Clinical | Trillium Therapeutics Inc | Hematologic Neoplasms; Ovarian Neoplasms; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Carcinoma, Ovarian Epithelial; Skin Neoplasms; Multiple Myeloma; Lymphoma, Follicular; Primary mediastinal B cell lymphoma; Peritoneal Neoplasms; Lymphoma; Fallopian Tube Neoplasms; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell; Leukemia, Myeloid, Acute | Details |
DSP-107 | DSP-107; KAHR-107 | Phase 2 Clinical | Kahr Medical | Solid tumours; Leukemia, Myelomonocytic, Chronic; Myelodysplastic Syndromes; Colorectal Neoplasms; Leukemia, Myeloid, Acute; Carcinoma, Non-Small-Cell Lung | Details |
LB-101 (Centessa Pharmaceuticals) | LB-101 (Centessa Pharmaceuticals); LB-101 Tetravalent PD-L1xCD47 LockBody bispecific monoclonal antibody | Phase 2 Clinical | Centessa Pharmaceuticals Plc | Solid tumours | Details |
ISB-1442 | ISB 1442; ISB-1442 | Phase 2 Clinical | Ichnos Sciences Sa | Multiple Myeloma; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, Myeloid, Acute | Details |
PT-886 | PT-886; PT886 | Phase 2 Clinical | Phanes Therapeutics Inc | Solid tumours; Esophageal Neoplasms; Stomach Neoplasms; Pancreatic Neoplasms; Carcinoma, Pancreatic Ductal | Details |
IMM-2902 | IMM-2902 | Phase 2 Clinical | ImmuneOnco Biopharmaceuticals (Shanghai) Co Ltd | Solid tumours; Stomach Neoplasms; Breast Neoplasms; Cholangiocarcinoma; Lung Neoplasms | Details |
6MW-3211 | 6MW3211; 6MW-3211 | Phase 2 Clinical | Mabwell (Shanghai) Bioscience Co Ltd | Carcinoma, Renal Cell; Myelodysplastic Syndromes; Neoplasms; Leukemia, Myeloid, Acute; Lung Neoplasms; Lymphoma | Details |
HX-009 | HX-009 | Phase 2 Clinical | Hanx Biopharmaceutical Co Ltd, Wuhan Hanxiong Biotechnology Co Ltd | Solid tumours; Liver Neoplasms; Stomach Neoplasms; Lymphoma | Details |
CC-90002 | INBRX-103; CC-90002 | Phase 1 Clinical | Inhibrx | Hematologic Neoplasms; Myelodysplastic Syndromes; Leukemia, Myeloid, Acute | Details |
Anti-CD47 monoclonal antibody (Biocad) | Phase 1 Clinical | Biocad | Neoplasms | Details | |
IMC-002(Immuneoncia) | IMC-002; 3D-197; 3D197 | Phase 1 Clinical | Immuneoncia Therapeutics Inc | Solid tumours; Hematologic Neoplasms; Neoplasms; Lymphoma; Neoplasm Metastasis | Details |
Recombinant humanized monoclonal antibody MIL95 (Mabworks/Connaught Biomedical Technology) | MIL-95; CM-312 | Phase 1 Clinical | Beijing Mabworks Biotech Co Ltd | Solid tumours; Neoplasms; Leukemia, Myeloid, Acute; Lymphoma | Details |
Zeripatamig | NI-1701; TG-1801 | Phase 1 Clinical | Novimmune Sa | Lymphoma, B-Cell | Details |
SL-172154 | SL-172154 | Phase 1 Clinical | Shattuck Labs Inc | Ovarian Neoplasms; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Ovarian Epithelial; Myelodysplastic Syndromes; Peritoneal Neoplasms; Fallopian Tube Neoplasms; Carcinoma, Squamous Cell; Leukemia, Myeloid, Acute | Details |
Urabrelimab | SRF-231 | Phase 1 Clinical | Surface Oncology Inc | Hematologic Neoplasms; Solid tumours | Details |
Simridarlimab | IBI-322; IBI322 | Phase 1 Clinical | Innovent Biologics(Suzhou) Co Ltd | Hematologic Neoplasms; Solid tumours; Bone Marrow Neoplasms; Neoplasms; Leukemia, Myeloid, Acute; Lymphoma; Lymphoma, T-Cell | Details |
ZL-1201 | ZL-1201 | Phase 1 Clinical | Zai Lab (Shanghai) Co Ltd | Hematologic Neoplasms; Solid tumours; Neoplasms | Details |
AUR-103 | AUR-103 | Phase 1 Clinical | Aurigene | Leukemia; Solid tumours; Myelodysplastic Syndromes; Lymphoma, Non-Hodgkin; Leukemia, Myeloid, Acute | Details |
HMPL-A83 | HMPL-A-83; HMPL-A83 | Phase 1 Clinical | Hutchison Medipharma Ltd | Solid tumours; Hematologic Neoplasms; Neoplasms | Details |
NI-1801 | NI-1801 | Phase 1 Clinical | Light Chain Bioscience Ltd | Solid tumours; Triple Negative Breast Neoplasms; Carcinoma, Ovarian Epithelial; Carcinoma, Non-Small-Cell Lung | Details |
AK-132 | AK132; AK-132 | Phase 1 Clinical | Zhongshan Akeso Biopharma Co Ltd | Solid tumours; Neoplasms | Details |
HCB-101 | HCB-101 | Phase 1 Clinical | HanchorBio Inc | Solid tumours; Lymphoma, Non-Hodgkin | Details |
D3L-001 | D3L-001 | Phase 1 Clinical | D3 Bio (Wuxi) Co Ltd | Solid tumours; Neoplasms | Details |
FP-002 (Fapon Biopharma) | FP-002 | Phase 1 Clinical | Fapon Biotech Inc | Solid tumours; Neoplasms | Details |
AUR-105 | AUR-105 | Phase 1 Clinical | Aurigene | Solid tumours; Hodgkin Disease; Lymphoma, Non-Hodgkin | Details |
BC-007 (Dragonboat Biopharmaceutical) | BC-007 | Phase 1 Clinical | Dragonboat Biopharmaceutical | Solid tumours; Neoplasms | Details |
BSI-082 | BSI-082 | Phase 1 Clinical | Boaoxin Biotechnology(Nanjing) Co Ltd | Hematologic Neoplasms; Solid tumours | Details |
SG-1906 | SG-1906; SG1906 | Phase 1 Clinical | Hangzhou Sumgen Biotechnology Co Ltd | Solid tumours; Neoplasms | Details |
SG-2501 | SG-2501 | Phase 1 Clinical | Hangzhou Sumgen Biotechnology Co Ltd | Hematologic Neoplasms; Lymphoma | Details |
PT-217 | PT-217 | Phase 1 Clinical | Phanes Therapeutics Inc | Solid tumours; Small Cell Lung Carcinoma; Pancreatic neuroendocrine tumors (pNET); Prostatic Neoplasms; Carcinoma, Neuroendocrine | Details |
LD-002 | LD-002 | Phase 1 Clinical | Zhejiang Blue Shield Pharmaceutical Co Ltd | Hematologic Neoplasms; Solid tumours; Lymphoma, Non-Hodgkin | Details |
SHS-009 | SHS-009; SH009; SH-009 | Phase 1 Clinical | Nanjing Sanhome Pharmaceutical Co Ltd | Neoplasms | Details |
Monoclonal Antibody (Mab) sB24M | Phase 1 Clinical | Swiss Biopharma Med GmbH | Pyoderma Gangrenosum; Pyoderma | Details | |
IMM-2520 | IMM-2520 | Phase 1 Clinical | ImmuneOnco Biopharmaceuticals (Shanghai) Co Ltd | Solid tumours; Squamous Cell Carcinoma of Head and Neck; Small Cell Lung Carcinoma; Breast Neoplasms; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
BAT-7104 | BAT-7104 | Phase 1 Clinical | Bio-Thera Solutions Ltd | Solid tumours; Neoplasms | Details |
STI-6643 | STI-6643 | Phase 1 Clinical | Sorrento Therapeutics Inc | Solid tumours; Neoplasms | Details |
PF-07257876 | Phase 1 Clinical | Pfizer Inc | Ovarian Neoplasms; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Non-Small-Cell Lung | Details | |
TQB-2928 | TQB-2928 | Phase 1 Clinical | Jiangsu Chia Tai-Tianqing Pharmaceutical Co Ltd | Hematologic Neoplasms; Solid tumours; Myelodysplastic Syndromes; Neoplasms; Leukemia, Myeloid, Acute | Details |
JMT-601 | JMT-601 | Phase 1 Clinical | Shanghai Jmt-Bio Inc | Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin | Details |
IMM2505 | IMM2505; IMM-2505 | Phase 1 Clinical | SunHo (China) BioPharmaceutical Co Ltd, ImmuneOnco Biopharmaceuticals (Shanghai) Co Ltd | Solid tumours | Details |
SG12473 | SG12473; SG-12473 | Phase 1 Clinical | Hangzhou Sumgen Biotechnology Co Ltd | Hematologic Neoplasms; Solid tumours; Neoplasms | Details |
SG404 | SG-404; SG404 | Phase 1 Clinical | Hangzhou Sumgen Biotechnology Co Ltd | Neoplasms | Details |
Kintuzumab(GenSci) | Phase 1 Clinical | Changchun GeneScience Pharmaceuticals Co Ltd | Solid tumours; Hematologic Neoplasms; Myelodysplastic Syndromes; Lymphoma, Non-Hodgkin; Leukemia, Myeloid, Acute; Lymphoma | Details | |
Letaplimab | IBI-188 | Phase 1 Clinical | Innovent Biologics(Suzhou) Co Ltd | Solid tumours; Adenocarcinoma of Lung; Neoplasms; Myelodysplastic Syndromes; Osteosarcoma; Leukemia, Myeloid, Acute | Details |
This web search service is supported by Google Inc.